Outlook Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Outlook Therapeutics is Russ Trenary, benoemd in Jul2021, heeft een ambtstermijn van 2.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.76M, bestaande uit 34.1% salaris en 65.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.7% van de aandelen van het bedrijf, ter waarde € 1.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 4.8 jaar.

Belangrijke informatie

Russ Trenary

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris	34.1%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Russ Trenary's beloning veranderd ten opzichte van Outlook Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

Compensatie versus markt: De totale vergoeding ($USD 1.76M ) Russ } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 792.59K ).

Compensatie versus inkomsten: De vergoeding van Russ is gestegen terwijl het bedrijf verliesgevend is.

CEO

Russ Trenary (65 yo)

2.8yrs

Tenure

US$1,758,862

Compensatie

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% € 4.5k
C. Trenary	President	2.8yrs	US$1.76m	0.70% € 1.2m
Lawrence Kenyon	Executive VP	8.6yrs	geen gegevens	0.0042% € 7.3k
Jeffrey Evanson	Chief Commercial Officer	5.4yrs	US$718.20k	0.18% € 310.1k
Alicia Tozier	Senior Vice President	2.1yrs	geen gegevens	geen gegevens
Joel Prieve	Senior Vice President of Licensing and M&A	2.2yrs	geen gegevens	geen gegevens
Surendra Sharma	Senior Vice President of Medical Affairs	1.3yrs	geen gegevens	geen gegevens
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	geen gegevens	geen gegevens
Jedd Comiskey	Senior VP - Head of Europe	less than a year	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 41ON wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% € 4.5k
C. Trenary	President	2.8yrs	US$1.76m	0.70% € 1.2m
Lawrence Kenyon	Executive VP	5.7yrs	geen gegevens	0.0042% € 7.3k
Kurt Hilzinger	Independent Director	8.3yrs	US$95.00k	0.11% € 181.5k
Julia Haller	Independent Director	1.7yrs	US$79.00k	0% € 0
Julian Gangolli	Independent Non-Employee Director	4yrs	US$112.50k	0% € 0
Arun Pillai	Board Observer	no data	geen gegevens	geen gegevens
Gerd Auffarth	Independent Non-Employee Director	4yrs	US$79.00k	0% € 0
Faisal Sukhtian	Independent Director	6.6yrs	US$113.00k	0.015% € 26.1k
Yezan Haddadin	Independent Director	6.5yrs	US$110.00k	0.023% € 38.7k
Andong Huang	Independent Director	3.8yrs	US$75.00k	0% € 0

4.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 41ON wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Outlook Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Recent updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Forecast breakeven pushed back to 2024

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021

Chief Operating Officer recently sold €134k worth of stock

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Recent Financing Secures Funding to Support Ons-5010 / Lytenava™ Through Planne Bla Submission

New 90-day high: €1.39

New 90-day high: €1.07

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New 90-day high: €1.04

Outlook Therapeutics, Inc. Announces Board Appointments

Outlook Therapeutics, Inc. announced that it has received $10 million in funding

Outlook Therapeutics, Inc. Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-Vikg for Advanced Macular Degeneration

New 90-day low - €0.58

Earnings released

Outlook Therapeutics, Inc. announced that it has received $1 million in funding from Syntone Ventures LLC

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam